Literature DB >> 16310246

Effect of naringin collagen graft on bone formation.

Ricky W K Wong1, A Bakr M Rabie.   

Abstract

Naringin is a flavonoid available commonly in citrus fruits and is also a HMG-CoA reductase inhibitor. Our laboratory compared the amount of new bone produced by naringin in collagen matrix to that produced by bone grafts and collagen matrix. Twenty bone defects, 5 mm x 10 mm were created in the parietal bone of 14 New Zealand White rabbits. In the experimental group, 5 defects were grafted with naringin solution mixed with collagen matrix, 5 defects were grafted with autogenous endochondral bone. In the control groups, 5 defects were grafted with collagen matrix alone (active control) and 5 were left empty (passive control). Animals were killed on day 14 and the defects were dissected and prepared for histological assessment. Serial sections were cut across each defect. Quantitative analysis of new bone formation was made on 150 sections (50 sections for each group) using image analysis. A total of 284% and 490% more new bone was present in defects grafted with naringin in collagen matrix than those grafted with bone and collagen, respectively. No bone was formed in the passive control group. In conclusion, naringin in collagen matrix have the effect of increasing new bone formation locally and can be used as a bone graft material.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310246     DOI: 10.1016/j.biomaterials.2005.11.009

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  13 in total

Review 1.  Review of the Applications of Biomedical Compositions Containing Hydroxyapatite and Collagen Modified by Bioactive Components.

Authors:  Agnieszka Sobczak-Kupiec; Anna Drabczyk; Wioletta Florkiewicz; Magdalena Głąb; Sonia Kudłacik-Kramarczyk; Dagmara Słota; Agnieszka Tomala; Bożena Tyliszczak
Journal:  Materials (Basel)       Date:  2021-04-21       Impact factor: 3.623

2.  Effect of bio-oss collagen and collagen matrix on bone formation.

Authors:  R W K Wong; A B M Rabie
Journal:  Open Biomed Eng J       Date:  2010-03-09

3.  Efficacy of Simvastatin in Bone Regeneration After Surgical Removal of Mandibular Third Molars: A Clinical Pilot Study.

Authors:  Anil Singh Chauhan; Anisha Maria; Anil Managutti
Journal:  J Maxillofac Oral Surg       Date:  2014-10-22

4.  A novel porous gelatin composite containing naringin for bone repair.

Authors:  Kuo-Yu Chen; Kuen-Cherng Lin; Yueh-Sheng Chen; Chun-Hsu Yao
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-04       Impact factor: 2.629

5.  Effects of Naringin on Proliferation and Osteogenic Differentiation of Human Periodontal Ligament Stem Cells In Vitro and In Vivo.

Authors:  Lihua Yin; Wenxiao Cheng; Zishun Qin; Hongdou Yu; Zhanhai Yu; Mei Zhong; Kemo Sun; Wei Zhang
Journal:  Stem Cells Int       Date:  2015-05-20       Impact factor: 5.443

6.  Naringin inhibits vascular endothelial cell apoptosis via endoplasmic reticulum stress‑ and mitochondrial‑mediated pathways and promotes intraosseous angiogenesis in ovariectomized rats.

Authors:  Wen-Ji Shangguan; Yue-Hui Zhang; Zhan-Chun Li; Lu-Min Tang; Jiang Shao; He Li
Journal:  Int J Mol Med       Date:  2017-09-28       Impact factor: 4.101

Review 7.  Natural Products from Chinese Medicines with Potential Benefits to Bone Health.

Authors:  Chun-Tao Che; Man Sau Wong; Christopher Wai Kei Lam
Journal:  Molecules       Date:  2016-02-27       Impact factor: 4.411

8.  Effect of quercetin on preosteoblasts and bone defects.

Authors:  R W K Wong; A B M Rabie
Journal:  Open Orthop J       Date:  2008-03-10

9.  The effects of Rhizoma Curculiginis and Rhizoma Drynariae extracts on bones.

Authors:  Ricky W K Wong; Bakr Rabie; Margareta Bendeus; Urban Hägg
Journal:  Chin Med       Date:  2007-12-19       Impact factor: 5.455

10.  The Function of Naringin in Inducing Secretion of Osteoprotegerin and Inhibiting Formation of Osteoclasts.

Authors:  Tong Xu; Lu Wang; You Tao; Yan Ji; Feng Deng; Xiao-Hong Wu
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.